{
  "docId": "019de074-2e24-777e-87b3-831358a7e33a",
  "docSlug": "971513439f6499291689438a6a6dd75f",
  "documentTitle": "Compass Therapeutics | Investor Presentation Deck | 20 slides",
  "authorId": "compass-therapeutics",
  "authorName": "Compass Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 20,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "traction",
  "function": "show_traction",
  "density": "balanced",
  "nDataPoints": 8,
  "notes": "Comparison of CTX-009 efficacy metrics (ORR, PFS, OS) against FOLFOX and TOPAZ-1 benchmarks.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-2e24-777e-87b3-831358a7e33a/11",
  "deckHref": "/decks/019de074-2e24-777e-87b3-831358a7e33a",
  "deckJsonHref": "/decks/019de074-2e24-777e-87b3-831358a7e33a.json",
  "deckAnchorHref": "/decks/019de074-2e24-777e-87b3-831358a7e33a#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.42,
        "x": 0.06,
        "y": 0.32
      },
      "kind": "list",
      "text": "24 patients with BTC have been enrolled and dosed; 10 partial responses (PRs) for a 37.5% ORR in patients treated in the second- and third-line settings (64% ORR of patients treated in the 2nd line setting); Median PFS 9.4 months; Median OS 12.5 months; Adverse event profile similar to Phase 1 studies",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "68d4fb16-2690-45f0-aee0-b9d5ec276888",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.42,
        "x": 0.53,
        "y": 0.32
      },
      "kind": "list",
      "text": "Other regimens in BTC; FOLFOX (NCCN guidelines): 5% ORR in the second-line setting, 4.0 month median PFS, 6.2 month median OS; TOPAZ-1 (Phase 3 study): 26.7% ORR for Gem/Cis/Durvalumab (anti PD-L1) in the first-line setting",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a55e0076-a6a2-4aee-a849-7a9ece7b9d81",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.6,
        "x": 0.04,
        "y": 0.16
      },
      "kind": "title",
      "text": "CTX-009 Interim Phase 2 Study Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d35a8bdf-fbe5-4336-945e-9717dae226e9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}